Innovative Alzheimer therapy: A new Research Agreement between BioArctic and Eisai initiated

BioArctic Neuroscience AB announces today that a new research agreement has been initiated between BioArctic and the Japanese pharmaceutical company Eisai. The research will lead to a new innovative treatment of Alzheimer´s disease. The treatment aims to affect the pathology of the disease, halt the disease progression and give the patients a better quality of life.

BioArctic and Eisai have a very successful collaboration since more than 10 years. Our previous research collaboration has led to an innovative treatment for Alzheimer’s disease, BAN2401.

BAN2401 is the first monoclonal antibody in clinical trials that selectively binds and eliminates protofibrils of beta-amyloid [1,2,3]. These soluble toxic aggregates lead to degeneration of brain cells, causing Alzheimer’s disease. BAN2401 aims to halt the progression of the disease and the continuous cognitive decline in Alzheimer patients.

BAN2401 is currently studied in a clinical trial with up to 800 Alzheimer patients at early disease stage aiming at evaluating the effect on cognition and biomarkers reflecting the progression of the disease. Eisai is driving the clinical program and the development of BAN2401 in collaboration with BioArctic.

“We are excited about the new research collaboration with Eisai, which is a world leading pharmaceutical company in Alzheimer’s disease research and it is a clear evidence of our previous longstanding successful collaboration. Eisai is a very important collaborator for BioArctic, and we hope that this new research will lead to a new treatment for Alzheimer’s patients that complement BAN2401, says Gunilla Osswald, CEO at BioArctic Neuroscience.

For further information, please contact:

BioArctic Neuroscience AB
Gunilla Osswald, CEO
Phone: +46-8-695 69 33

2. The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-b Protofibrils in Brain and Cerebrospinal Fluid of tg ArcSwe Mice, Stina Tucker et al, Journal of Alzheimer´s Disease 43 (2015) 575-588
3. Perspectives on future Alzheimer therapies: amyloid-b protofibrils – a new target for immunotherapy with BAN2401 in Alzheimer´s disease; Lars Lannfelt et al. Alzheimer´s Research & Therapy 2014, 6:16